Curing Patients Not Sustainable: Goldman Sachs

"The potential to deliver 'one shot cures' is one of the most attractive aspects of gene therapy, genetically-engineered cell therapy and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies," analyst Salveen Richter wrote in the note to clients Tuesday.

Okay, I have to say "At least they're honest about it" but I couldn't help but shudder at the fact that there are actual--natural--human beings thinking about revenues when it comes to curing people. I'm thinking AI ain't got nothing on us, superintelligent or not.

Now, someone will say but revenues mean jobs, blah-blah. Sure, poor biotech firms were nothing until gene therapy was invented.

Share this post

Link to post
Share on other sites
Sign in to follow this  
Followers 0